THE INVESTOR

메뉴열기
March 29, 2024

Analysts downplay Samsung BioLogics’ delisting

PUBLISHED : November 15, 2018 - 15:27

UPDATED : November 15, 2018 - 15:39

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Analysts here downplayed on Nov. 15 the potential delisting of Samsung BioLogics following a ruling by Korea’s financial regulator that the sixth-highest valued company on KOSPI is guilty of accounting irregularities. 

The contract drug manufacturer will wait for a decision from the country’s bourse operator if it should come under review for 15 business days while preparing for an administrative suit to overturn the Financial Services Commission’s ruling. 




RELATED:
Trading of Samsung BioLogics shares halted


Amid mounting concerns over the company with a market cap of 22 trillion won (US$19.50 billion), Daishin Securities analyst Hong Ga-hye said the probability of delisting is low given that all the companies that have gone through the deliberation process so far have maintained their listing status.

“There is a limited possibility of delisting as the stock exchange will systematically consider the company’s operational sustainability and management transparency as well as investor protection (for the decision),” she said.

With no clear date given on how long the trading halt will continue, uncertainties surrounding the firm will be persistent and dampen investor sentiment toward biopharmaceutical stocks in the short term, NH Investment & Securities analyst Ku Wan-sung said. 


Here is a timeline of the upcoming decision on Samsung BioLogics shares

Following the ruling, the Korea Exchange will decide whether the company should come under review for potential delisting in 15 business days by Dec. 5. The period can be extended for an additional 15 days if necessary.

If it is subjected to the deliberation, a review committee will be convened within 20 days and then make a conclusion on delisting in seven days. 

Samsung BioLogics can raise objections in seven days if it receives an order to delist. 

Trading suspension could continue for up to 57 days while the procedures are completed.

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.